Shuren Highlights CDRH Actions To Ease Trial Burdens On Capitol Hill
This article was originally published in The Gray Sheet
Executive Summary
CDRH Director Jeffrey Shuren participated in the first roundtable of a newly launched House Energy and Commerce Committee initiative to accelerate drug and device development. He emphasized the device center’s recent proposals to minimize pre-market data collection with postmarket controls, and supported the promise of clinical trial networks.
You may also be interested in...
FDA Will Face Reforms, Oversight In Republican Congress – Analysts
Election gains will embolden Republicans to put FDA in Congress’ oversight “crosshairs,” as members of key Senate and House panels scrutinize how the agency is using its resources. Reforms could also come soon as part of the ongoing 21st Century Cures initiative.
FDA Will Face Reforms, Oversight In Republican Congress – Analysts
Election gains will embolden Republicans to put FDA in Congress’ oversight “crosshairs,” as members of key Senate and House panels scrutinize how the agency is using its resources. Reforms also could come soon as part of the ongoing 21st Century Cures initiative.
FDA Will Face Reforms, Oversight In Republican Congress, Analysts Say
Election gains by Republicans will embolden Congress to put FDA in its oversight “crosshairs,” as members of key Senate and House panels scrutinize how the agency is using its resources. Reforms could also come soon as part of the ongoing 21st Century Cures initiative.